



IRW

1645

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ROBINSON *et al.*

Application No.: 09/942,583

Filed: August 31, 2001

For: **Neisserial Vaccine Compositions
and Methods**

Confirmation No.: 9616

Art Unit: 1645

Examiner: Minnifield, N. M.

Atty. Docket: 1581.0840001/RWE

Statement of Substance of Interview

Mail Stop Issue Fee

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In reply to the Supplemental Notice of Allowability and Interview Summary Form PTOL-413 mailed November 21, 2006, and in accordance with 37 C.F.R. § 1.133(b) and MPEP § 713.04, Applicants' undersigned representative provides the following statement of the substance of the interview held with the Examiner in the above-captioned application.

The Examiner and Applicants' undersigned representative participated in a telephonic interview on November 17, 2006. During this interview, the Examiner agreed that claim 23 may be canceled from the application in order to avoid an obviousness-type double patenting rejection. Applicants' undersigned representative agreed to the cancellation of claim 23 by examiner's amendment, thus concluding the interview.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert W. Esmond
Attorney for Applicants
Registration No. 32,893

Date: December 4, 2006

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

ALL INFORMATION CONTAINED
HEREIN IS UNCLASSIFIED